Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23671800 | 0.91 | TSHR (0.50) | TSHR | |
| SCHEMBL24588411 | 0.89 | TSHR (0.43) | TSHR | |
| SCHEMBL24587820 | 0.89 | TSHR (0.41) | TSHR | |
| SCHEMBL15134519 | 0.85 | TSHR (0.44) | TSHR | |
| SCHEMBL24588713 | 0.84 | TSHR (0.39) | TSHR | |
| SCHEMBL24587939 | 0.82 | TSHR (0.48) | TSHR | |
| SCHEMBL24588818 | 0.82 | TSHR (0.43) | TSHR | |
| SCHEMBL31578781 | 0.80 | TSHR (0.50) | TSHR | |
| SCHEMBL24587816 | 0.78 | TSHR (0.48) | TSHR | |
| SCHEMBL22589944 | 0.78 | TSHR (0.48) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262819-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | Beam Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| CN-116887841-A | Nanomaterials comprising ester-linked acetals | 比姆医疗股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022140252-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140252-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | LIPA, SGMS1, SGMS2 | TSHR 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.